ABOUT THE EVENT
Date: Wednesday, November 4, 2026 10–11am EST
Event Location: Virtual
Scala Biodesign combines AI with physics-based calculations to design antibody frameworks and antigen-binding regions, building on a decade of development across antibodies, vaccines, gene therapies and other biotherapeutics.
In this session, co-founders Dr. Ravit Netzer (CEO) and Dr. Adi Goldenzweig (CTO) draw on Scala’s work with top-10 pharma companies and biotechs to walk through experimental antibody case studies: the starting problem, the sequence changes designed, and how variants compare with the parent antibody across affinity and developability assays — which properties improved and which were retained.
You’ll learn how Scala’s design framework addresses:
Stability: aggregation, self-association, polyreactivity and expression yields
Activity: affinity and selectivity
Program constraints: controlling the location and load of mutations
Sequence diversity: antibodies with diverse sequences and V-gene combinations that meet binding and developability requirements, giving teams multiple candidates to advance
Antigens: an antigen design module to improve the expression and stability of antigens and drug targets
Teams developing scFvs, VHHs, multispecifics or ADCs can use the session to assess which design approaches are worth testing in their own programs.
